Conatus Scores Fast Track for Emricasan

Conatus has snagged fast track designation for emricasan for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis.

The company plans to focus first on patients with NASH cirrhosis and will develop the drug in parallel for patients with NASH fibrosis, and supportive clinical trials addressing additional patient populations. The drug is in Phase 2 studies.